Israel-based Dune Medical Devices has announced the closing of a $12.5 million Series B investment led by Apax Partners, who invested $11.5 million in the round. The funding will be used to complete pivotal clinical studies of Dune's BP and console system in the U.S.
The BP probe and console system developed by Dune uses patent-protected, proprietary radiofrequency (RF) spectroscopy that enables intraoperative, on-contact, measurement of suspected tissue surfaces.
Dune also announced that it has received the EU CE Mark designation for its disposable BP probe and console system. The intended use for the probe and system is to enable intraoperative, on-contact measurement of suspected tissue surfaces during a lumpectomy (partial mastectomy) procedure. The CE mark permits Dune to market its device throughout the EU.